Steroid plus sirolimus for mild autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether adding sirolimus (a medication that calms the immune system) to standard steroid treatment is better than steroids alone for people newly diagnosed with mild autoimmune hemolytic anemia (AIHA). It may help control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with mild autoimmune hemolytic anemia and need treatment to calm your immune system.
- You have active hemolysis (red blood cells breaking down) with a hemoglobin level of 100 g/L or lower.
- Your Coombs test is positive (a blood test that shows your immune system is attacking your red blood cells).
- You do not have lupus or other connective tissue diseases (mild blood test changes are okay).
- Your liver, kidney, and performance status are within acceptable limits, and you have not received long-term steroids or other immunosuppressants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not improved with other treatments. It aims to see if this therapy can help control the disease and improve blood counts.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
Hear when a new Autoimmune Hemolytic Anemia (AIHA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.